Vitamin D, blood tests and clinical outcomes
In this investigation
Start with the question the food record can answer
My linked food estimate contains about 4 µg vitamin D, with incomplete composition evidence. I reported that I had not taken vitamin D. A planned purchase is not a dose, and there is no documented blood result here. The vitamin D guide explains the intake references and an ordinary source; the bone interaction page discusses fracture trials and calcium.
The trial-reading guide separates outcome questions and evidence levels.
Training: closer populations still produce mixed results
A 2026 report followed 250 young male Army recruits, starting winter training with low blood vitamin D common. Its four randomized arms used oral D3, simulated sunlight or their respective placebos. The oral regimen was 1,000 IU daily for four weeks, then 400 IU for eight; investigators pooled both active arms for the injury analysis. Blood status improved, but there was no clear reduction in lower-body overuse injuries. Carswell et al., 2026.
This was a secondary analysis of a trial designed for other outcomes. Injury estimates were imprecise, and events after the 12-week intervention were explicitly exploratory follow-up. Fourteen bone-stress injuries were too few for a separate analysis. The result neither establishes equivalence nor tests treatment of my reported shoulder pain. It also differs from the female-recruit trial of calcium plus vitamin D already discussed on the bone page.
A small earlier experiment randomized 28 men to 4,000 IU D3 daily or placebo around a damaging jumping protocol. A first-day force-recovery calculation favored D, but force and power across measurement times and muscle soreness did not differ clearly. The authors changed their planned comparison after observing weakness in the control leg. USANA supplied the supplements and employed two authors. This is a signal for further study, rather than established injury treatment or sustained strength improvement. Barker et al., 2013.
Fresh evidence also illustrates the difference between inflammation and recovery. A September 2026 trial randomized 30 active men, analyzing 27, after 21 days of 10,000 IU D3 daily or placebo. Selected inflammatory markers changed; repeated Wingate cycling performance did not clearly improve, and functional recovery was not measured. Its cited registry currently describes different populations and longer training protocols, leaving prospective outcome specification unclear. That high research dose is not a proposed routine. Grześkiewicz et al., 2026, cited registry.
Respiratory illness: symptom burden and prevention are distinct
An earlier publication from the same recruit trial reported fewer symptom-days and lower peak cold severity with supplementation. Cold prevalence and average duration were not clearly reduced overall. These were self-reported symptom outcomes in 134 of the 250 randomized recruits, selected for intervention and diary compliance, with several comparisons. This is not independent replication of the later injury trial or proof of fewer medically confirmed infections. Harrison et al., 2021.
The larger CORONAVIT study randomized 6,200 UK participants aged 16 or older to an offer of testing followed by 800 or 3,200 IU daily when eligible, or no offer. 5,979 contributed follow-up. Neither offer reduced its primary outcome of doctor- or swab-confirmed respiratory infection over six months, despite higher vitamin D measurements. Almost half the control group reported some supplement use, and profound deficiency was uncommon. CORONAVIT, 2022.
This open-label trial tested a practical test-and-treat strategy, rather than perfectly separated supplement exposure. It included supplement-industry funding, with no funder role reported. It weakens the case for buying testing and higher-dose supplements solely to prevent respiratory illness in this setting; it does not settle treatment of a diagnosed deficiency or every infection population.
Aging: a biomarker result is not extra years of life
In 2025, a VITAL ancillary analysis reported less leukocyte telomere shortening with 2,000 IU D3 daily over four years: a difference of 0.14 kilobases, 95% CI 0.007–0.27. It came from the same parent trial as the guide’s fracture and cancer reports. 1,031 participants had at least one measurement, but only 660 had a year-four sample. Authors described it as a post hoc analysis of a completed trial; exploratory subgroup results were unadjusted for multiple comparisons. The reported result concerns a blood-cell biomarker in older adults, not demonstrated longer survival or better training recovery. Zhu et al., 2025.
An independent D-Health analysis found no clear telomere benefit among 1,519 older Australians receiving 60,000 IU monthly or placebo. It measured relative telomere length at year four or five, without a baseline measurement. Its regimen and endpoint differ from VITAL, so the disagreement does not identify a superior dosing schedule. Rahman et al., 2023. The parent trial’s primary all-cause mortality result also showed no clear benefit: hazard ratio 1.04, 95% CI 0.93–1.18. That directly measured clinical outcome should remain distinct from aging-marker claims. D-Health mortality report, 2022.
Another 2025 aging-clock report used 777 older Swiss participants from DO-HEALTH. This post hoc analysis tested vitamin D, omega-3 and exercise across several methylation clocks. The clearest individual signal was for omega-3; vitamin D alone did not consistently improve the clocks. A combined-treatment finding on one clock cannot establish vitamin D as a standalone anti-aging intervention. Clinical survival was not established by these clock changes. DO-HEALTH Bio-Age, 2025.
Testing should answer a clinical question
The current USPSTF recommendation finds insufficient evidence to assess routine screening’s benefit and harm in asymptomatic, community-dwelling adults. That is an insufficient-evidence statement, rather than a ban on testing. It excludes people with relevant symptoms or conditions needing management. USPSTF, 2021.
The vitamin D guide explains the Endocrine Society’s distinction between ordinary requirements and routine testing.
If I take a supplement, I will record its product and dose in the food log.
A food estimate does not diagnose deficiency or explain my shoulder discomfort. Clinically indicated assessment remains separate.